Pharmacokinetic drug evaluation of ceftobiprole for the treatment of MRSA

ABSTRACT

Introduction: Methicillin-resistant Staphylococcus aureus (MRSA), while decreasing in overall incidence, is still a prominent concern world-wide. New agents coming to market in the last 10 years allow practitioners to optimize treatment for MRSA infections. Ceftobiprole is a cephalosporin agent with MRSA activity, currently approved in selected countries for the treatment of community-acquired pneumonia and hospital-acquired pneumonia.

Areas covered: Relevant literature regarding spectrum of activity, pharmacokinetics, pharmacodynamics, and clinical trials will be discussed.

Expert opinion: Ceftobiprole is an addition to a growing number of antimicrobials with activity against MRSA. Concern for appropriate dosing in critically ill patients remains due to its ineffectiveness for the treatment of ventilator-associated pneumonia (VAP). While ceftobiprole has activity against gram-negative organisms, the allowance for use of an additional agent for gram-negative infections in clinical trials limits recommendations for monotherapy for empirical treatment of HAP. Ceftobiprole’s place in therapy will lie in its activity against gram positive organisms, such as Streptococcus spp. and Staphylococcus spp.

KEYWORDS:

• Methicillin-resistant Staphylococcus aureus
• community-acquired bacterial pneumonia
• hospital-acquired pneumonia
• ceftobiprole

Declaration of interest

LH Danzinger has acted as speaker and consultant for Allergan. KA Rodvold is a consultant for Johnson & Johnson and has been involved in previous research on this drug. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Additional information

Funding

This paper was not funded.